Raging Capital Hopes To Profit On Biotech Crash – ValueWalk Premium

Raging Capital Hopes To Profit On Biotech Crash

Activist hedge fund, Raging Capital Management, managed by William C Martin gained 0.8% net of all fees and expenses during the second quarter. Year to date the fund is up 1.8% net, according to a letter to investors reviewed by ValueWalk.

Since inception (April 2006) the Raging Capital Master Fund -- Series B has returned 620.6%, a compound annual growth rate of 23.8%, compared to the S&P 500's total return of 94%, a CAGR of 7.4%.


This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email support@valuewalk.com or click chat.

Saved Articles

The Life and Career of Charlie Munger

Charlie is more than just Warren Buffett’s friend and Berkshire Hathaway’s Vice Chairman – Buffett has actually credited him with redefining how he looks at investing. Now you can learn from Charlie firsthand via this incredible ebook and over a dozen other famous investor studies by signing up below:

  • Learn from the best and forever change your investing perspective
  • One incredible tidbit of knowledge after another in the page-turning masterpiece of a book
  • Discover the secrets to Charlie’s success and how to apply it to your investing
Never Miss A Story!
Subscribe to ValueWalk Newsletter. We respect your privacy.

What’s missing today for many investors is real, straightforward advice.

Especially when it comes to Value Investing and Hedge Funds. 💵

That’s what makes ValueWalk Premium different. Some would say we’re “unusual.”

Our subscribers look forward to clear, easy-to-understand information they can act on.

Sign up for  today for only a few dollars a day and get a 3 day no obligation trial with a targeted 20% discount coupon code.

Cancel anytime during trial and you are never charged.

Limited time offer: For first 50 subscribers